within Pharmacolibrary.Drugs.ATC.G;

model G03AC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0005,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03AC04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Quingestanol is a synthetic progestin derivative that has been used in the past as an oral contraceptive component. It is a prodrug of norethisterone. Quingestanol is not widely approved or in clinical use today; most formulations have been discontinued in favor of newer progestins.</p><h4>Pharmacokinetics</h4><p>No primary pharmacokinetic publications or clinical pharmacokinetic profiles reporting parameters for quingestanol in humans were found. Limited data exist, and estimates are generated based on knowledge of similar progestin prodrugs (such as norethisterone acetate).</p><h4>References</h4><ol><li><p>Di Carlo, FJ, et al., &amp; Barr, WH (1974). Quingestanol acetate metabolism in women. <i>Pharmacology</i> 11(5) 287–303. DOI:<a href=\"https://doi.org/10.1159/000136501\">10.1159/000136501</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4853997/\">https://pubmed.ncbi.nlm.nih.gov/4853997</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03AC04;
